NanoCarrier NC-6300-001 (Sarcoma)
What is the Purpose of this Study?
Part 1 is looking for the best dose of a study drug called NC-6300 for people with solid tumors.
Part 2 will look at the activity and safety of the drug when combined with Olaratumab in patients with soft tissue sarcoma.
In Part 1, patients will receive an intravenous infusion of NC-6300 on day 1 of each 21-day cycle until they have bad side effects or their disease gets worse.
In Part 2, patients will receive the best dose identified in Part 1 on day 1 of each 21 day cycle plus Olaratumuab on days 1 and 8 of each cycle until they have bad side effects or their disease gets worse.
All patients will go through a screening period with physical exams, testing and questionnaires.
While receiving the study drug, all patients will have testing on days 1, 8 and 15 of each cycle.
Patients in Part 1 will also have several blood tests throughout the day on day 1 of each cycle.
Who Can Participate in this Study?
Adult men and women who have:
Part 1: a diagnosis of advanced solid tumor, including sarcomas that are not responding to standard therapy
Part 2: a diagnosis of advanced, unresectable or metastatic soft tissue sarcoma not eligible for curative treatment with surgery or radiation.
What is Involved?
We are doing this study to find out how safe and effective a study drug called Nanoparticle Epirubicin (NC-6300) is for men and women with advanced cancer.